Therapeutic agents useful for treating pain

Details Therapeutic agents useful for treating pain Therapeutic agents useful for treating pain

2010-03-02

2011-10-04

Bernhardt, Emily (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C544S360000

Reexamination Certificate

active

08030310

ABSTRACT:
Compounds of formulae:where X is S or O and Ar2, R1, R2, R3, R8, n, m, t, and v are disclosed herein, or a pharmaceutically acceptable salt thereof (a “3-substituted Pyridyl Compound”), compositions comprising an effective amount of a 3-substituted Pyridyl Compound, and methods for treating or preventing pain, urinary incontinence, an ulcer, inflammatory-bowel disease, irritable-bowel syndrome, an addictive disorder, Parkinson's disease, parkinsonism, anxiety, epilepsy, stroke, a seizure, a pruritic condition, psychosis, a cognitive disorder, a memory deficit, restricted brain function, Huntington's chorea, amyotrophic lateral sclerosis, dementia, retinopathy, a muscle spasm, a migraine, vomiting, dyskinesia or depression in an animal comprising administering to an animal in need thereof an effective amount of a 3-substituted Pyridyl Compound are disclosed herein.

REFERENCES:
patent: 3536809 (1970-10-01), Applezweig
patent: 3598123 (1971-08-01), Zaffaroni
patent: 3845770 (1974-11-01), Theeuwes et al.
patent: 3916899 (1975-11-01), Theeuwes et al.
patent: 4008719 (1977-02-01), Theeuwes et al.
patent: 5039680 (1991-08-01), Imperato et al.
patent: 5059595 (1991-10-01), Le Grazie
patent: 5073543 (1991-12-01), Marshall et al.
patent: 5075341 (1991-12-01), Mendelson et al.
patent: 5120548 (1992-06-01), McClelland et al.
patent: 5198459 (1993-03-01), Imperato et al.
patent: 5232934 (1993-08-01), Downs
patent: 5354556 (1994-10-01), Sparks et al.
patent: 5556837 (1996-09-01), Nestler et al.
patent: 5556838 (1996-09-01), Mayer et al.
patent: 5574052 (1996-11-01), Rose et al.
patent: 5591767 (1997-01-01), Mohr et al.
patent: 5639476 (1997-06-01), Oshlack et al.
patent: 5674533 (1997-10-01), Santus et al.
patent: 5698155 (1997-12-01), Grosswald et al.
patent: 5733566 (1998-03-01), Lewis
patent: 5762925 (1998-06-01), Sagen
patent: 6136839 (2000-10-01), Isakson et al.
patent: 6204284 (2001-03-01), Beer et al.
patent: 6239267 (2001-05-01), Duckworth et al.
patent: 6335180 (2002-01-01), Julius et al.
patent: 6406908 (2002-06-01), McIntyre et al.
patent: 6723730 (2004-04-01), Bakthavatchalam et al.
patent: 6864261 (2005-03-01), Gharagozloo et al.
patent: 6974818 (2005-12-01), Kyle et al.
patent: 7071335 (2006-07-01), Kyle et al.
patent: 7157462 (2007-01-01), Sun et al.
patent: 7256193 (2007-08-01), Kyle et al.
patent: 7262194 (2007-08-01), Kyle et al.
patent: 7279493 (2007-10-01), Kyle et al.
patent: 7342017 (2008-03-01), Kyle et al.
patent: 7582635 (2009-09-01), Sun et al.
patent: 7696208 (2010-04-01), Kyle et al.
patent: 2005/0009841 (2005-01-01), Zheng et al.
patent: 2005/0080095 (2005-04-01), Zheng et al.
patent: 2007/0142360 (2007-06-01), Sun et al.
patent: 2008/0200472 (2008-08-01), Kyle et al.
patent: 2009/0042902 (2009-02-01), Sun et al.
patent: 3440141 (1986-05-01), None
patent: 549039 (1995-08-01), None
patent: 2001-261657 (2001-09-01), None
patent: 2001-328938 (2001-11-01), None
patent: 2003-192673 (2003-07-01), None
patent: WO 00/39117 (2000-07-01), None
American Chemical Society, “Bis(trichloromethyl) carbonate as an alternative reagent for phosgene,”Chem. Abstr. 106:4294d (1987), Eckert.
Bartho et al., “Involvement of Capsaicin-Sensitive Neurones in Hyperalgesia and Enhanced Opioid Antinociception in Inflammation,”Naunyn-Schmiedeberg's Archives Pharmacol. 342:666-670 (1990).
Berkow et al., “Crohn's Disease,”The Merck Manual of Medical Information528-530 (1997).
Berkow et al., “Irritable Bowel Syndrome,”The Merck Manual of Medical Information525-526 (1997).
Berkow et al., “Peptic Ulcer,”The Merck Manual of Medical Information496-500 (1997).
Berkow et al., “Seizure Disorders,”The Merck Manual of Medical Information, pp. 345-350 (1997).
Berkow et al., “Stroke,”The Merck Manual of Medical Information, pp. 352-355 (1997).
Berkow et al., “Ulcerative Proctitis,”The Merck Manual of Medical Information530-532 (1997).
Berkow et al., “Urinary Incontinence,”The Merck Manual of Medical Information631-634 (1997).
Bevan et al., “Vanilloid Receptors: Pivotal molecules in Nocciception,”Current Opinions in CPNS Investigational Drugs, 2(2):178-185 (2000).
Brunton, “Agents for Control of Gastric Acidity and Treatment of Peptic Ulcers,”Goodman and Gilman's The Pharmacological Basis of Therapeuticspp. 901-915 (Goodman et al., eds., 9thed., McGraw-Hill, New York 1996).
Buchwald et al., “Long-term, Continuous Intravenous Heparin Administration by an Implantable Infusion Pump in Ambulatory Patients with Recurrent Venous Thrombosis,”Surgery88:507-516 (1980).
Chiamulera et al., “Reinforcing and Locomotor Stimulant Effects of Cocaine are Absent in mGluR5 Null Mutant Rice,”Nature Neurosci. 4(9):873-874 (2001).
Chong et al., “Multilevel selectivity in the mild and high-yielding chlorosilane-induced cleavage of carbamates to isocyanates,”J. Org. Chem. 63(23):8515-8521 (1998).
Cooke, “Glycopyrrolate in Bladder Dysfunction,”SA Medical J. 63:3 (1983).
Cotarca et al., “Bis(trichloromethyl) Carbonate in Organic Synthesis, Synthesis,”J. Synthetic Org. Chem. 5:553-576 (1996).
D'Amour et al., “A Method for Determining Loss of Pain Sensation,”J. Pharmacol. Exp. Ther. 72:74-79 (1941).
De Costa et al., “A Practical Synthesis of Isotopically Labeled 1-(4-isothiocyanatophenyl)-4-(t-butyl)-2,6,7-trioxabicyclo-[2.2.2]-octane, a Probe for the Benzodiazepine Receptor-coupled Chloride Ionophore,”Heterocycles32:2343-2355 (1991).
Di Marzo et al., “Endovanilloid Signaling in Pain,”Current Opinion in Neurobiology11:372-379 (2002).
Dogrul et al., “Peripheral and Spinal Antihyperalgesic Activity of SIB-1757, A Metabotropic Glutamate Receptor (mGluR5) Antagonist, in Experimental Neuropathic Pain in Rats,”Neurosci. Lett. 292(2):115-118 (2000).
During et al., “Controlled Release of Dopamine from a Polymeric Brain Implant: In Vivo Characterization,”Ann. Neurol. 25:351-356 (1989).
Eckert et al., “Triphosgene, a crystalline phosgene substitute,”Angew. Chem. Int. Ed. Engl. 26:894-895 (1987).
Erhardt et al., “Cardiotonic Agents. 5. Fragments from the heterocycle-phenyl-imidazole pharmacophore,”J. Med. Chem. 32(6):1173-1176 (1989).
Erhardt et al., “Cardiotonic agents,”Synlett11:1784-1786 (1999).
European Patent Office, Communication pursuant to Article 94(3) EP for application No. 08150839.2-2117 (Aug. 27, 2009).
Foley, “Pain,”Cecil Textbook of Medicine, pp. 100-107 (1996).
Fundytus et al., “In vivo Antinociceptive Activity of Anti-Rat mGluR1and mGluR5Antibodies in Rats,”NeuroReport9:731-735 (1998).
Fundytus et al., “Knockdown of Spinal Metabotropic Glutamate Receptor 1 (mGluR1) Alleviates Pain and Restores Opioid Efficacy after Nerve Injury in Rats,”Brit. J. Pharmacol. 132:354-367 (2001).
Fundytus, “Glutamate Receptors and Nociception Implications for the Drug-Treatment of Pain,”CNS Drugs15:29-58 (2001).
Fundytus et al., “Antisense Oligonucleotide Knockdown of mGluR1Alleviates Hyperalgesia and Allodynia Associated with Chronic Inflammation,”Pharmacol., Biochem. &Behavior73:401-410 (2002).
Goodson, “Dental Applications,”Medical Applications of Controlled Release, vol. 2, pp. 115-138 (1984).
Greene, “Protection for the Hydroxyl Group Including 1,2- and 1,3-Diols,”Protective Groups in Organic Synthesispp. 10-86, John Wiley & Sons, New York (1981).
Grupp et al., “Protection against Hypoxia-reoxygenation in the Absence of Poly (ADP-ribose) Synthetase in Isolated Working Hearts,”J. Mol. Cell Cardiol. 31:297-303 (1999).
Hanson, “Analgesic, Antipyretic and Anti-Inflammatory Drugs,”Remington: The Science and Practice of Pharmacy, vol. II 1196-1221 (Gennaro ed. 19thed. 1995).
Hargreaves et al., “A New and Sensitive Method for Measuring Thermal Nociception in Cutaneous

Affiliated with

Also associated with

Rating

Therapeutic agents useful for treating pain does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutic agents useful for treating pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents useful for treating pain will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4285019